Korff et al. (4) has considerable therapeutic implications, as their findings suggest that targeting expression of mutant HNRNPH2, such as with an antisense oligonucleotide, may induce compensatory expression of HNRNPH1 and consequently ameliorate the symptoms of hnRNPH2-related NDD. This evidence concerns the gene HNRNPH1 and Neurodevelopmental delay.